Newswise — Sept. 17, 2020 – The ATS Research Program is pleased to announce a new one-year grant supporting sarcoidosis research. The award by Mallinckrodt Pharmaceuticals provides $50,000 in funding. 

Sarcoidosis is an inflammatory disease that affects the lungs, lymph glands, and other organs. The latest ATS guideline, published in March 2020, details the challenges associated with the illness. One of the authors of the guideline noted “the diagnosis of sarcoidosis is never fully certain.” Therefore, research support that will improve clinical outcomes is critical. 

“The ATS Research Program/Mallinckrodt Pharmaceuticals Fellowship in Sarcoidosis is a prestigious international award designed to provide critical resources to promising early career investigators who aspire to improve the lives of our patients,” said Elliot D. Crouser, MD, co-author of the ATS clinical practice guideline on sarcoidosis.  “This funding mechanism will foster scientific mentorship and hands-on research experience to establish the basic skills required for a productive academic career in the field of sarcoidosis research.” 

“Mallinckrodt is honored to sponsor the ATS Research Program/Mallinckrodt Pharmaceuticals Fellowship in Sarcoidosis as part of our commitment to furthering understanding of this complex and difficult-to-diagnose disease,” said Steven Romano, MD, executive vice president and chief scientific officer at Mallinckrodt. “We look forward to the important work we expect will be produced by the early career investigators the fellowship supports.” 

The application process will open Oct. 1, 2020.

Interested applicants may read more about this grant opportunity here.

About the ATS Research Program The American Thoracic Society and its Research Program are improving respiratory health worldwide by supporting young investigators in pulmonary, critical care, and sleep medicine. The ATS Research Program, established in 2004, bolsters new investigators as they strive to launch independent research careers dedicated to innovation in patient care.

Since 2004, the Research Program has awarded $19.3 million in research grants to 263 investigators who have gone on to secure more than $330 million in federal funding.

About Mallinckrodt

Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The company's Specialty Brands reportable segment’s areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com.

 

MEDIA CONTACT
Register for reporter access to contact details